secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENSAR, Inc. (LNSR)
CIK:        0001320350
Form:       8-K
Filed at:   2021-11-08T23:59:59+00:00
Accession:  0001564590-21-055056
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENSAR Q3 2021 revenue $8.3M (+16% YoY), net loss widens to $6.2M
-----------------------------------------------------------------

- Revenue $8.3M, up 16% YoY; procedure volumes grew 23% over Q3 2020.
- Net loss of $6.2M ($0.65 loss per share) vs. $4.8M loss ($0.64 per share) in Q3 2020.
- R&D spending surged 59% to $3.2M, driven by development of ALLY Adaptive Cataract Treatment System.
- Cash and equivalents $32.3M; cash utilization $2.2M in the quarter.
- Adjusted EBITDA was ($3.9M) compared to ($0.4M) in Q3 2020, reflecting higher R&D and SG&A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1320350/000156459021055056/0001564590-21-055056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1320350/000156459021055056/lnsr-8k_20211108.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-055056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer